From clinic to practice in NSCLC patients with exon 20 mutations

Bookmark and Share
Published: 13 Sep 2022
Views: 487
Prof Nicolas Girard - Institut Curie, Paris, France

Prof Nicolas Girard talks about clinical practice in NSCLC patients with exon 20 mutations.

He explains how key biomarker testing is, and looks at real world data from ESMO 2022 that shows the importance of identifying exon 20 mutations.

Prof Girard discusses amivantamab compared with European, real-world standard of care in adults with advanced non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations, after the failure of platinum-based therapy.

He also mentions similar research in Japanese patients and concludes by discussing the toxicity and management of these treatment options.

This programme is supported by an unrestricted educational grant from Janssen.